IDH1/2 Mutational Analysis in AML Patients: Diagnosis and Follow-up
Completed
- Conditions
- Acute Myeloid Leukemia
- Registration Number
- NCT04242849
- Lead Sponsor
- Josep Carreras Leukaemia Research Institute
- Brief Summary
In a spanish series of AML patients it is intended to perform, at the moment of diagnosis, pyrosequencing of IDH1 and IDH2 genes. Taking into account the incidence of AML in the area, it is planed to study 100 patients per year.
Among the cases with IDH1/2 mutations, targeted deep sequencing (TDS) of a panel covering coding regions of 40 myeloid related genes will be applied. With TDS, pyrosequencing results will be validated at the same time that prognosis value of co-mutated genes could be studied. Furthermore, with TDS, molecular architecture of IDH1 and IDH2 mutated cases might be better understood.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 354
Inclusion Criteria
- Patients >18 years old with de novo acute myeloid leukemia will be included. All patients will be treated according to clinical routine.
Exclusion Criteria
- Patients not following the above criteria.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Presence of IDH1/2 mutation 1 day Detection of mutations in IDH1 and IDH2 genes
- Secondary Outcome Measures
Name Time Method Detection of co-mutations 1 day Screening of aditional mutations in those cases with IDH1/2 mutation